Hideyuki Takedani

List of Publications by Year
in descending order

33	284	933447 10	940533 16
papers	citations	h-index	g-index

33	33	33	382
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selfâ€monitoring has potential for home exercise programmes in patients with haemophilia. Haemophilia, 2014, 20, e121-7.	2.1	41
2	Strategies to encourage physical activity in patients with hemophilia to improve quality of life. Journal of Blood Medicine, 2016, 7, 85.	1.7	28
3	First report on the safety and efficacy of an extended halfâ€life glyco<scp>PEG</scp>ylated recombinant <scp>FVIII</scp> for major surgery in severe haemophilia A. Haemophilia, 2017, 23, 689-696.	2.1	22
4	Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasmaâ€derived factor VIII. Haemophilia, 2010, 16, 740-746.	2.1	21
5	A phase <scp>III</scp> clinical trial of a mixture agent of plasmaâ€derived factor <scp>VII</scp>a and factor X (<scp>MC</scp>710) in haemophilia patients with inhibitors. Haemophilia, 2017, 23, 59-66.	2.1	19
6	Deep venous thrombosis was not detected after total knee arthroplasty in Japanese patients with haemophilia. Haemophilia, 2015, 21, 585-588.	2.1	15
7	Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. Haemophilia, 2010, 16, 290-295.	2.1	14
8	The risk of elective orthopaedic surgery for haemophilia patients: Japanese single-centre experience. Haemophilia, 2013, 19, 951-955.	2.1	14
9	Joint Function and Arthropathy Severity in Patients with Hemophilia. Journal of the Japanese Physical Therapy Association, 2015, 18, 15-22.	0.1	14
10	Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII . Patient Preference and Adherence, 2019, Volume 13, 497-513.	1.8	14
11	Interâ€observer reliability of three different radiographic scores for adult haemophilia. Haemophilia, 2011, 17, 134-138.	2.1	10
12	Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia. Haemophilia, 2019, 25, e223-e230.	2.1	10
13	Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A. Haemophilia, 2020, 26, 867-872.	2.1	10
14	Physical activity and its related factors in Japanese people with haemophilia. Haemophilia, 2019, 25, e267-e273.	2.1	8
15	Risk factors for postoperative complications of orthopedic surgery in patients with hemophilia: Second report. Journal of Orthopaedics, 2018, 15, 558-562.	1.3	7
16	Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent. Haemophilia, 2016, 22, e459-61.	2.1	6
17	Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A. Drug Design, Development and Therapy, 2015, 9, 1767.	4.3	5
18	Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors. Blood Coagulation and Fibrinolysis, 2019, 30, 385-392.	1.0	5

#	Article	IF	Citations
19	Total hip arthroplasty and total knee arthroplasty in a patient with congenital deficiency of plasminogen activator inhibitorâ€1. Haemophilia, 2016, 22, e237-9.	2.1	3
20	Arthroscopic debridement for advanced haemophilic ankle arthropathy. Haemophilia, 2017, 23, e479-e481.	2.1	3
21	Perioperative safety and hemostatic efficacy of AdvateÂ® in patients with hemophilia A in a postmarketing surveillance in Japan. International Journal of Hematology, 2018, 108, 22-29.	1.6	3
22	Extension contracture stiff knee in haemophilia: Surgical timing and procedure for total knee arthroplasty. Modern Rheumatology, 2023, 33, 851-855.	1.8	3
23	Rehabilitation improved walking ability for three haemophilia patients with inhibitors. Haemophilia, 2014, 20, e222-4.	2.1	2
24	A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor <scp>VIII</scp> inhibitor eradication. Haemophilia, 2016, 22, e228-31.	2.1	2
25	The Haemophilia Joint Visualizer: development of a personalized, interactive, webâ€based tool to help improve adherence to prophylaxis. Haemophilia, 2017, 23, e155-e158.	2.1	2
26	Orthotropic live transplantation for cirrhosis from hepatitis C virus leads to correction of factor IX deficiency allowing for ankle arthroplasty without factor replacement in a patient with moderate haemophilia B. Blood Coagulation and Fibrinolysis, 2018, 29, 131-134.	1.0	1
27	Longâ€term impact of haemarthrosis on arthropathy and activities of daily living in Japanese persons with haemophilia. Haemophilia, 2020, 26, e124-e127.	2.1	1
28	AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab â€“ protocol for a multicentre, open-label, phase IV clinical study. BMJ Open, 2022, 12, e059667.	1.9	1
29	The features of clearance in recombinant factor IX (BeneFIXÂ®). Haemophilia, 2015, 21, 702-707.	2.1	0
30	Usefulness of a simple selfâ€administered joint condition assessment sheet to predict the need for orthopaedic intervention in the management of haemophilic arthropathy. Haemophilia, 2017, 23, e116-e123.	2.1	0
31	A case report on a multicentre cooperative rehabilitation programme for inhibitorâ€positive patients with haemophilia A. Haemophilia, 2018, 24, e248-e252.	2.1	0
32	Surgical treatment of haemophilic pseudotumor with severe bone destruction: a case report. Modern Rheumatology Case Reports, 2021, 5, 414-420.	0.7	0
33	First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol,) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	0